Dilek Yazıcıoğlu Ünal1, İlkay Baran1, Murad Mutlu2, Gülçin Ural1, Taylan Akkaya1, Onur Özlü1. 1. Clinic of Anaesthesiology and Reanimation, Ministry Health Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey. 2. Clinic of Otorhinolaryngology, Ministry Health Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.
Abstract
OBJECTIVE: To compare sugammadex and neostigmine regarding the efficacy in reversing rocuronium-induced neuromuscular block, the incidence of post-operative respiratory complications and costs in patients undergoing surgery for the treatment of obstructive sleep apnoea (OSA). METHODS: After obtaining ethical approval and patient consent, 74 patients in ASA physical status I or II were randomised into two groups to receive 2-mg kg(-1) sugammadex (Group S) or 0.04-mg kg(-1) neostigmine+0.5-mg atropine (Group N). Groups were compared regarding time to TOF (train-of-four) 0.9, operating room time, post-anaesthesia care unit (PACU) stay, post-operative respiratory complications, costs related to neuromuscular block reversal, anaesthesia care and complication treatment. RESULTS:Patient demographics, anaesthesia, surgical data and total rocuronium doses were similar between groups. Time to TOF 0.9 was shorter for group S [Group N: 8 (5-18) min; Group S: 2 (1.5-6) min (p<0.001)]. Operating room time [Group S: 72.4±14.3 min; Group N: 96.6±22.8 min (p<0.001)] and PACU stay [Group S: 22.9±10.1 dk; Group N: 36.3±12.6 dk (p<0.001)] were also shorter in Group S. After extubation, desaturation was observed in 12 (32.4%) patients in group N and in 4 (8%) patients in group S (p=0.048). In group N, three patients were reintubated; there were eight (21.6%) unplanned intensive care unit (ICU) admissions. There was one unplanned ICU admission in group S. Negative pressure pulmonary oedema was observed in one patient in group N. The results regarding costs were as follows. The reversal cost was higher in the sugammadex group (vial cost 98.14 TL) than that in the neostigmine group (ampoule cost 0.27 TL; total 6147.88 TL vs. 3569.5 TL); however, complication treatment cost and total cost were lower in group S than those in group N (199.5 TL vs. 3944.6 TL) (staff anaesthesia doctor cost was 0.392 TL per min and the cost of nurse anaesthetist was 0.244 TL per min). CONCLUSION: This study confirmed the efficacy of sugammadex over neostigmine for the reversal of rocuronium-induced neuromuscular block. Sugammadex decreases the incidence of post-operative respiratory complications and related costs in patients with OSA.
RCT Entities:
OBJECTIVE: To compare sugammadex and neostigmine regarding the efficacy in reversing rocuronium-induced neuromuscular block, the incidence of post-operative respiratory complications and costs in patients undergoing surgery for the treatment of obstructive sleep apnoea (OSA). METHODS: After obtaining ethical approval and patient consent, 74 patients in ASA physical status I or II were randomised into two groups to receive 2-mg kg(-1) sugammadex (Group S) or 0.04-mg kg(-1) neostigmine+0.5-mg atropine (Group N). Groups were compared regarding time to TOF (train-of-four) 0.9, operating room time, post-anaesthesia care unit (PACU) stay, post-operative respiratory complications, costs related to neuromuscular block reversal, anaesthesia care and complication treatment. RESULTS:Patient demographics, anaesthesia, surgical data and total rocuronium doses were similar between groups. Time to TOF 0.9 was shorter for group S [Group N: 8 (5-18) min; Group S: 2 (1.5-6) min (p<0.001)]. Operating room time [Group S: 72.4±14.3 min; Group N: 96.6±22.8 min (p<0.001)] and PACU stay [Group S: 22.9±10.1 dk; Group N: 36.3±12.6 dk (p<0.001)] were also shorter in Group S. After extubation, desaturation was observed in 12 (32.4%) patients in group N and in 4 (8%) patients in group S (p=0.048). In group N, three patients were reintubated; there were eight (21.6%) unplanned intensive care unit (ICU) admissions. There was one unplanned ICU admission in group S. Negative pressure pulmonary oedema was observed in one patient in group N. The results regarding costs were as follows. The reversal cost was higher in the sugammadex group (vial cost 98.14 TL) than that in the neostigmine group (ampoule cost 0.27 TL; total 6147.88 TL vs. 3569.5 TL); however, complication treatment cost and total cost were lower in group S than those in group N (199.5 TL vs. 3944.6 TL) (staff anaesthesia doctor cost was 0.392 TL per min and the cost of nurse anaesthetist was 0.244 TL per min). CONCLUSION: This study confirmed the efficacy of sugammadex over neostigmine for the reversal of rocuronium-induced neuromuscular block. Sugammadex decreases the incidence of post-operative respiratory complications and related costs in patients with OSA.
Authors: Jeffrey B Gross; Kenneth L Bachenberg; Jonathan L Benumof; Robert A Caplan; Richard T Connis; Charles J Coté; David G Nickinovich; Vivek Prachand; Denham S Ward; Edward M Weaver; Lawrence Ydens; Song Yu Journal: Anesthesiology Date: 2006-05 Impact factor: 7.892
Authors: T Fuchs-Buder; C Claudius; L T Skovgaard; L I Eriksson; R K Mirakhur; J Viby-Mogensen Journal: Acta Anaesthesiol Scand Date: 2007-08 Impact factor: 2.105
Authors: Glenn S Murphy; Joseph W Szokol; Jesse H Marymont; Steven B Greenberg; Michael J Avram; Jeffery S Vender Journal: Anesth Analg Date: 2008-07 Impact factor: 5.108
Authors: F Paton; M Paulden; D Chambers; M Heirs; S Duffy; J M Hunter; M Sculpher; N Woolacott Journal: Br J Anaesth Date: 2010-10-08 Impact factor: 9.166
Authors: Paul F White; Burcu Tufanogullari; Ozlem Sacan; Edward G Pavlin; Oscar J Viegas; Harold S Minkowitz; M E Hudson Journal: Anesth Analg Date: 2009-03 Impact factor: 5.108
Authors: G Della Rocca; L Pompei; C Pagan DE Paganis; S Tesoro; C Mendola; P Boninsegni; A Tempia; S Manstretta; L Zamidei; A Gratarola; P Murabito; L Fuggiano; P DI Marco Journal: Acta Anaesthesiol Scand Date: 2013-07-14 Impact factor: 2.105
Authors: Germán Echeverry; Lily Polskin; Luis E Tollinche; Kenneth Seier; Kay See Tan; Patrick J McCormick; Gregory W Fischer; Florence M Grant Journal: Perioper Care Oper Room Manag Date: 2021-07-16
Authors: Ákos I Fábián; Edömér Tassonyi; Vera Csernoch; Marianna Fedor; Tamás Sohajda; Lajos Szente; Béla Fülesdi Journal: BMC Anesthesiol Date: 2021-08-17 Impact factor: 2.217
Authors: Stavros G Memtsoudis; Crispiana Cozowicz; Mahesh Nagappa; Jean Wong; Girish P Joshi; David T Wong; Anthony G Doufas; Meltem Yilmaz; Mark H Stein; Megan L Krajewski; Mandeep Singh; Lukas Pichler; Satya Krishna Ramachandran; Frances Chung Journal: Anesth Analg Date: 2018-10 Impact factor: 5.108